Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040664 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
A Phase 2 study of HIV Infection, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT00040664 is a Phase 2 study of HIV Infection that has completed, run by ViiV Healthcare. The registered enrollment target is 69 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00040664, a Phase 2 study of HIV Infection, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
Conditions Studied
Interventions
- DRUG ritonavir
- DRUG fosamprenavir
Study Locations (20)
New York
- GSK Investigational Site - New York
- GSK Investigational Site - New York
- GSK Investigational Site - Stony Brook
- GSK Investigational Site - The Bronx
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Tampa
North Carolina
- GSK Investigational Site - Chapel Hill
- GSK Investigational Site - Durham
Texas
- GSK Investigational Site - Dallas
- GSK Investigational Site - Fort Worth
Alabama
- GSK Investigational Site - Birmingham
California
- GSK Investigational Site - Los Angeles
Illinois
- GSK Investigational Site - Chicago
Louisiana
- GSK Investigational Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2002-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040664
The ClinicalTrials.gov registry entry for NCT00040664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (71% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which ritonavir is the first listed.
NCT00040664 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00040664 about?
NCT00040664 is a clinical study titled "A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years". This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
What is the current status of trial NCT00040664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2002-07. Estimated completion is 2008-10.
What conditions does trial NCT00040664 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00040664?
The interventions under investigation include: ritonavir (DRUG), fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00040664?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040664 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
ACTIVE NOT RECRUITING · Phase 2
-
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
COMPLETED · Phase 2
-
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
COMPLETED · Phase 2
-
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.